Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23Andme Holding Co. (NQ: ME )

0.5038 +0.1476 (+41.44%)
Streaming Delayed Price Updated: 1:03 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 52,810,996
Open 0.4708
Bid (Size) 0.5037 (2)
Ask (Size) 0.5042 (36)
Prev. Close 0.3562
Today's Range 0.4300 - 0.6190
52wk Range 0.3500 - 2.170
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Edges Lower; Bio-Path Holdings Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels

Performance

YTD
-44.54%
-44.54%
1 Month
+6.99%
+6.99%
3 Month
-20.95%
-20.95%
6 Month
-36.90%
-36.90%
1 Year
-75.54%
-75.54%

More News

Read More
Once Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's Future
Via Benzinga
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Looking Into 23andMe Holding's Recent Short Interest
Via Benzinga
Looking Into 23andMe Holding's Recent Short Interest
Via Benzinga
Is 23andMe Stock a Smart Buy Right Now?
Via The Motley Fool
Why Is Lithium Americas (LAC) Stock Down 28% Today?
Via InvestorPlace
Walgreens Layoffs 2024: What to Know About the Latest WBA Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
ME Stock Alert: CEO Anne Wojcicki Seeks to Save 23andMe in Take-Private Deal
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
23andMe announces CEO’s intention to pursue a potential take-private
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
From 23andMe, Inc.
Via GlobeNewswire
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?
Via The Motley Fool
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
From 23andMe, Inc.
Via GlobeNewswire
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
From 23andMe, Inc.
Via GlobeNewswire
A Few Years From Now, You'll Probably Wish You'd Followed Billionaire Investors Into This Stock
Via The Motley Fool
23andMe Launches New Genetic Reports on Common Forms of Cancer
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
From 23andMe, Inc.
Via GlobeNewswire
Why Intuitive Machines Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Former YouTube CEO's Teenaged Son Found Dead At UC Berkeley
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Crude Oil Gains 3%; Kellanova Posts Upbeat Results
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Dow Tumbles Over 100 Points; US Initial Jobless Claims Fall Last Week
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.